Biomarkers for immunotherapy of hepatocellular carcinoma

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Cancer statistics, 2023

Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · see citing works

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406 · see citing works

International Agency for Research on Cancer

National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,493 · see citing works

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works

Hepatocellular carcinoma

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · see citing works

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771 · see citing works

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · see citing works

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,549 · see citing works

Hepatocellular Carcinoma

Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508 · see citing works

BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319 · cited 2× · see citing works

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,657 · see citing works

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · see citing works

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · see citing works

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Abou‐Alfa, G. K., Meyer, T., Cheng, A., El-Khoueiry, A. B., Rimassa, L., Ryoo, B., Çiçin, İ., Merle, P., Chen, Y.-H., Park, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,347 · see citing works

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Escudier, B. J., Porta, C., Schmidinger, M., Ferran Algaba, B., Patard, J., Khoo, V. S., Eisen, T. G., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,253 · see citing works

Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing

Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152 · see citing works

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · see citing works

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855 · see citing works

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works

Surgery and portal hypertension.

Child, C. G., & Turcotte, J. (1964) · PubMed · Cited by 1,793 · see citing works

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789 · see citing works

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · see citing works

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743 · see citing works

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Zhu, A. X., Kang, Y., Yen, C., Finn, R. S., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,666 · see citing works

Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma

Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624 · see citing works

PD-1/PD-L1 pathway: current researches in cancer.

Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 1,602 · see citing works

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576 · see citing works

Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508 · see citing works

Pan-cancer single-cell landscape of tumor-infiltrating T cells

Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402 · see citing works

The microbiome and human cancer

Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332 · see citing works

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273 · see citing works

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · see citing works

Mass Cytometry: Single Cells, Many Features

Spitzer, M. H., & Nolan, G. P. (2016) · Cell · doi:10.1016/j.cell.2016.04.019 · Cited by 1,199 · see citing works

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167 · see citing works

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124 · see citing works

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106 · see citing works

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Vogel, A., Cervantes, A. M. R., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J., Neumann, U. P., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,047 · see citing works

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

Klein, E. A., Richards, D., Cohn, A. L., Tummala, M., Lapham, R. L., Cosgrove, D. O., Chung, G. G., Clement, J., Gao, J., Hunkapiller, N. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.806 · Cited by 1,014 · see citing works

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009 · see citing works

Liquid Biopsy: From Discovery to Clinical Application

Alix‐Panabières, C., & Pantel, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1311 · Cited by 983 · see citing works

Liver tumour immune microenvironment subtypes and neutrophil heterogeneity

Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiao, X., Liu, H., Feng, M., Wang, F., Cheng, J., Zhao, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05400-x · Cited by 956 · see citing works

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934 · see citing works

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · see citing works

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

Sun, Y., Wu, L. L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., Zhang, Z., Xie, J., Wang, C., Chen, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.041 · Cited by 893 · see citing works

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B. Q., Kelly, M. C., Rae, Z., Hernandez, J. M., Davis, J. L., Martin, S. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.007 · Cited by 844 · see citing works

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

Duffy, A. G., Ulahannan, S. V., Makarova‐Rusher, O. V., Rahma, O. E., Wedemeyer, H. H., Pratt, D. W., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 823 · see citing works

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 804 · see citing works

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · see citing works

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy

Liu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., Sun, L., Liu, Y., Du, Y., Guo, X., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.011 · Cited by 749 · see citing works

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · see citing works

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 700 · see citing works

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678 · see citing works

B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome

Fridman, W. H., Meylan, M., Petitprez, F., Sun, C., Italiano, A., & Sautès‐Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 667 · see citing works

Deep learning in cancer pathology: a new generation of clinical biomarkers

Echle, A., Rindtorff, N. T., Brinker, T. J., Luedde, T., Pearson, A. T., & Kather, J. N. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01122-x · Cited by 667 · see citing works

Harnessing multimodal data integration to advance precision oncology

Boehm, K. M., Khosravi, P., Vanguri, R., Gao, J., & Shah, S. P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00408-3 · Cited by 662 · see citing works

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Lo, Y. M. D., Han, D. S. C., Jiang, P., & Chiu, R. W. K. (2021) · Science · doi:10.1126/science.aaw3616 · Cited by 659 · see citing works

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652 · see citing works

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Vanhersecke, L., Brunet, M., Guégan, J., Rey, C., Bougoüin, A., Cousin, S., Moulec, S. L., Besse, B., Loriot, Y., Larroquette, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00232-6 · Cited by 647 · see citing works

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602 · see citing works

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma

Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597 · see citing works

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2571 · Cited by 562 · see citing works

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00326-6 · Cited by 535 · see citing works

ImmunoPET: Concept, Design, and Applications

Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 483 · see citing works

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472 · see citing works

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Kelley, R. K., Sangro, B., Harris, W. P., Ikeda, M., Okusaka, T., Kang, Y., Qin, S., Tai, D. W.-M., Lim, H. Y., Yau, T. C. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03555 · Cited by 450 · see citing works

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma

Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., Forgues, M., Pomyen, Y., Bhudhisawasdi, V., Lertprasertsuke, N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.009 · Cited by 434 · see citing works

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 412 · see citing works

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407 · see citing works

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00416-8 · Cited by 395 · see citing works

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 382 · see citing works

Modulating the microbiome to improve therapeutic response in cancer

McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376 · see citing works

Gut microbiome in HCC – Mechanisms, diagnosis and therapy

Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 370 · see citing works

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Ma, L., Wang, L., Khatib, S. A., Chang, C.-W., Heinrich, S., Dominguez, D. A., Forgues, M., Candia, J., Hernandez, M. O., Kelly, M. C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.028 · Cited by 370 · see citing works

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360 · see citing works

Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma

Ho, D. W., Tsui, Y., Chan, L., Sze, K. M., Zhang, X., Cheu, J. W., Chiu, Y., Lee, J. M., Chan, A. C. Y., Cheung, E. T.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24010-1 · Cited by 324 · see citing works

Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells

Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318 · see citing works

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Scheiner, B., Pomej, K., Kirstein, M. M., Hucke, F., Finkelmeier, F., Waidmann, O., Himmelsbach, V., Schulze, K., von Felden, J., Fründt, T., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.035 · Cited by 309 · see citing works

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A. M., Galanina, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18613-3 · Cited by 295 · see citing works

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A. B., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 294 · see citing works

Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy

Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B., & Livak, K. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00449-x · Cited by 282 · see citing works

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Kaseb, A. O., Hasanov, E., Cao, H. S. T., Xiao, L., Vauthey, J.-N., Lee, S. S., Yavuz, B. G., Mohamed, Y. I., Qayyum, A., Jindal, S., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00427-1 · Cited by 274 · see citing works

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Qin, S., Li, Q., Gu, S., Chen, X., Lin, L.-Z., Wang, Z., Xu, A., Chen, X., Zhou, C., Ren, Z., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00109-6 · Cited by 255 · see citing works

Big data in basic and translational cancer research

Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254 · see citing works

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253 · see citing works

Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses

Chew, V., Lai, L., Pan, L., Lim, C. J., Li, J., Ong, R., Chua, C. J. H., Leong, J. Y., Lim, K. H., Toh, H. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706559114 · Cited by 246 · see citing works

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J., O’Toole, S. A., Anderson, L. A., Scolyer, R. A., et al. (2020) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 245 · see citing works

Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma

Hung, M., Lee, J. S., Ma, C., Diggs, L. P., Heinrich, S., Chang, C.-W., Ma, L., Forgues, M., Budhu, A., Chaisaingmongkol, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21804-1 · Cited by 239 · see citing works

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00385-x · Cited by 239 · see citing works

Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and Patient Outcomes

Budhu, A., Roessler, S. K., Zhao, X., Yu, Z., Forgues, M., Ji, J., Karoly, E. D., Qin, L., Ye, Q., Jia, H., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.054 · Cited by 238 · see citing works

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Cohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01232-w · Cited by 235 · see citing works

MAIT Cells in Health and Disease

Provine, N. M., & Klenerman, P. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080719-015428 · Cited by 228 · see citing works

Neutrophils as potential therapeutic targets in hepatocellular carcinoma

Geh, D., Leslie, J., Rumney, R., Reeves, H. L., Bird, T. G., & Mann, D. A. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00568-5 · Cited by 222 · see citing works

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Qin, S., Chen, Z., Fang, W. J., Ren, Z., Xu, R., Ryoo, B., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00620 · Cited by 203 · see citing works

Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin

Ruf, B., Bruhns, M., Babaei, S., Kedei, N., Ma, L., Revsine, M., Benmebarek, M.-R., Ma, C., Heinrich, B., Subramanyam, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.026 · Cited by 200 · see citing works

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197 · see citing works

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Hu, X., Chen, R., Wei, Q., & Xu, X. L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64537 · Cited by 197 · see citing works

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Finn, R. S., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.031 · Cited by 187 · see citing works

T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

Barsch, M., Salié, H., Schlaak, A. E., Zhang, Z., Hess, M., Mayer, L., Tauber, C., Otto-Mora, P., Ohtani, T., Nilsson, T., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.032 · Cited by 187 · see citing works

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma

Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 175 · see citing works

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

Ang, C., Klempner, S. J., Ali, S. M., Madison, R. W., Ross, J. S., Severson, E. A., Fabrizio, D. A., Goodman, A. M., Kurzrock, R., Suh, J. H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26998 · Cited by 166 · see citing works

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Singal, A. G., Hoshida, Y., Pinato, D. J., Marrero, J. A., Nault, J., Paradis, V., Tayob, N., Sherman, M., Lim, Y., Feng, Z., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.233 · Cited by 164 · see citing works

Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer

Ma, L., Heinrich, S., Wang, L., Keggenhoff, F. L., Khatib, S. A., Forgues, M., Kelly, M. C., Hewitt, S. M., Saif, A., Hernandez, J. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35291-5 · Cited by 164 · see citing works

Detecting Liver Cancer Using Cell-Free DNA Fragmentomes

Foda, Z. H., Annapragada, A. V., Boyapati, K., Bruhm, D. C., Vulpescu, N. A., Medina, J. E., Mathios, D., Cristiano, S., Niknafs, N., Luu, H. T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0659 · Cited by 164 · see citing works

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

Feun, L. G., Li, Y., Wu, C., Wangpaichitr, M., Jones, P. D., Richman, S. P., Madrazo, B. L., Kwon, D., Garcia-Buitrago, M. T., Martin, P. B., et al. (2019) · Cancer · doi:10.1002/cncr.32339 · Cited by 160 · see citing works

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications

Martín-Serrano, M. A., Kepecs, B., Torres‐Martín, M., Bramel, E. R., Haber, P. K., Merritt, E., Rialdi, A., Param, N. J., Maeda, M., Lindblad, K. E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326514 · Cited by 159 · see citing works

Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging

Chen, S., Feng, S., Wei, J., Liu, F., Li, B., Li, X., Hou, Y., Gu, D., Tang, M., Xiao, H., et al. (2019) · European Radiology · doi:10.1007/s00330-018-5986-x · Cited by 157 · see citing works

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

Agdashian, D., ElGindi, M., Xie, C., Sandhu, M., Pratt, D. W., Kleiner, D. E., Figg, W. D., Rytlewski, J. A., Sanders, C. M., Yusko, E. C., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02299-8 · Cited by 150 · see citing works

MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma

Hectors, S. J. C. G., Lewis, S. C., Besa, C., King, M. J., Said, D., Putra, J., Ward, S. C., Higashi, T., Thung, S. N., Shen, Y., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06675-2 · Cited by 148 · see citing works

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145 · see citing works

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Murai, H., Kodama, T., Maesaka, K., Tange, S., Motooka, D., Suzuki, Y., Shigematsu, Y., Inamura, K., Mise, Y., Saiura, A., et al. (2022) · Hepatology · doi:10.1002/hep.32573 · Cited by 141 · see citing works

Liquid biopsy in the clinical management of hepatocellular carcinoma

von Felden, J., Garcia-Lezana, T., Schulze, K., Losic, B., & Villanueva, A. (2020) · Gut · doi:10.1136/gutjnl-2019-320282 · Cited by 141 · see citing works

Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma

Nguyen, P. H. D., Ma, S., Phua, C. Z. J., Kaya, N. A., Lai, H. L. H., Lim, C. J., Lim, J. Q., Wasser, M., Lai, L., Tam, W. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20171-7 · Cited by 140 · see citing works

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01218-y · Cited by 140 · see citing works

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00995-8 · Cited by 136 · see citing works

Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy

Dharmapuri, S., Özbek, U., Lin, J., Sung, M. W., Schwartz, M., Branch, A. D., & Ang, C. (2020) · Cancer Medicine · doi:10.1002/cam4.3135 · Cited by 131 · see citing works

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Tamborero, D., Dienstmann, R., Rachid, M. H., Boekel, J., López‐Fernández, A., Jonsson, M., Razzak, A., Braña, I., Petris, L. D., Yachnin, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00332-x · Cited by 131 · see citing works

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

von Felden, J., Craig, A. J., Garcia-Lezana, T., Labgaa, I., Haber, P. K., D'Avola, D., Asgharpour, A., Dieterich, D., Bonaccorso, A., Torres-Martín, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01519-1 · Cited by 122 · see citing works

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Chuah, S., Lee, J. J. X., Song, Y., Kim, H., Wasser, M., Kaya, N. A., Bang, K., Lee, Y. J., Jeon, S. H., Suthen, S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.039 · Cited by 122 · see citing works

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

Zhu, A. X., Dayyani, F., Yen, C., Ren, Z., Bai, Y., Meng, Z., Pan, H., Dillon, P., Mhatre, S. K., Gaillard, V. E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3275 · Cited by 121 · see citing works

The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma

Heinrich, B., Gertz, E. M., Schäffer, A. A., Craig, A. J., Ruf, B., Subramanyam, V., McVey, J. C., Diggs, L. P., Heinrich, S., Rosato, U., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325288 · Cited by 117 · see citing works

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., Terstappen, L. W. M. M., & Groen, H. J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0649-2 · Cited by 116 · see citing works

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B. T. K., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 116 · see citing works

Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma

Castilla-Lièvre, M.-A., Franco, D., Gervais, P., Kühnast, B., Agostini, H., Marthey, L., Désarnaud, S., & Helal, B.-O. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3241-0 · Cited by 108 · see citing works

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Qin, S., Chen, Z., Fang, W. J., Ren, Z., Xu, R., Ryoo, B., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.383 · Cited by 108 · see citing works

Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma

Shao, Y., Liu, T., Hsu, C., Lu, L., Shen, Y., Lin, Z., Cheng, A., & Hsu, C. (2019) · Liver International · doi:10.1111/liv.14210 · Cited by 107 · see citing works

Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors

Winograd, P., Hou, S., Court, C. M., Lee, Y., Chen, P., Zhu, Y., Sadeghi, S., Finn, R. S., Teng, P., Wang, J. J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1577 · Cited by 106 · see citing works

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H. (2020) · Cancers · doi:10.3390/cancers12010182 · Cited by 105 · see citing works

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors

An, H. J., Chon, H. J., & Kim, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179414 · Cited by 105 · see citing works

Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy

Dercle, L., McGale, J., Sun, S. H., Marabelle, A., Yeh, R., Deutsch, É., Mokrane, F., Farwell, M. D., Ammari, S., Schöder, H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005292 · Cited by 99 · see citing works

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Qin, S., Chan, L. S., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.032 · Cited by 97 · see citing works

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Verset, G., Borbath, I., Karwal, M., Verslype, C., Vlierberghe, H. V., Kardosh, A., Zagonel, V., Stal, P. I., Sarker, D., Palmer, D. H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3807 · Cited by 92 · see citing works

A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma

Liu, J., Tang, W., Budhu, A., Forgues, M., Hernandez, M. O., Candia, J., Kim, Y., Bowman, E. D., Ambs, S., Zhao, Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.038 · Cited by 86 · see citing works

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

Myojin, Y., Kodama, T., Sakamori, R., Maesaka, K., Matsumae, T., Sawai, Y., Imai, Y., Ohkawa, K., Miyazaki, M., Tanaka, S., et al. (2022) · Cancers · doi:10.3390/cancers14040883 · Cited by 84 · see citing works

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Sun, X., Mei, J., Lin, W., Yang, Z., Peng, W. J., Chen, J., Zhang, Y., Xu, L., & Chen, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08428-w · Cited by 83 · see citing works

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Muhammed, A., Fulgenzi, C. A. M., Dharmapuri, S., Pinter, M., Balcar, L., Scheiner, B., Marron, T. U., Jun, T. W., Saeed, A., Hildebrand, H., et al. (2021) · Cancers · doi:10.3390/cancers14010186 · Cited by 83 · see citing works

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10358-z · Cited by 81 · see citing works

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

Yang, H., Kang, B., Ha, Y., Lee, S. H., Kim, I. H., Kim, H., Lee, W. S., Kim, G., Jung, S., Rha, S. Y., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100672 · Cited by 81 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Greten, T. F., Abou‐Alfa, G. K., Cheng, A., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002794 · Cited by 81 · see citing works

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients

Yuan, G., Song, Y., Li, Q., Hu, X., Zang, M., Dai, W., Cheng, X., Huang, W. M., Yu, W., Chen, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613946 · Cited by 80 · see citing works

Digital-resolution detection of microRNA with single-base selectivity by photonic resonator absorption microscopy

Canady, T. D., Li, N., Smith, L. D., Lu, Y., Kohli, M., Smith, A. M., & Cunningham, B. T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904770116 · Cited by 77 · see citing works

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Monge, C., Xie, C., Myojin, Y., Coffman, K., Hrones, D. M., Wang, S., Hernandez, J. M., Wood, B. J., Levy, E. B., Juburi, I., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005640 · Cited by 76 · see citing works

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Wu, L. Y., Fulgenzi, C. A. M., D’Alessio, A., Cheon, J., Nishida, N., Saeed, A., Wietharn, B., Cammarota, A., Pressiani, T., Personeni, N., et al. (2022) · Cancers · doi:10.3390/cancers14235834 · Cited by 75 · see citing works

Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma

Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 75 · see citing works

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

Matsumae, T., Kodama, T., Myojin, Y., Maesaka, K., Sakamori, R., Takuwa, A., Oku, K., Motooka, D., Sawai, Y., Oshita, M., et al. (2022) · Cancers · doi:10.3390/cancers14143367 · Cited by 74 · see citing works

Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges

McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 72 · see citing works

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

Yau, T. C. C., Zagonel, V., Santoro, A., Acosta-Rivera, M., Choo, S. P., Matilla, A., He, A. R., Gracián, A. C., El-Khoueiry, A. B., Sangro, B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00972 · Cited by 72 · see citing works

A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis

Fujiwara, N., Kobayashi, M., Fobar, A. J., Hoshida, A., Marquez, C. A., Koneru, B., Panda, G., Taguri, M., Qian, T., Raman, I., et al. (2021) · Med · doi:10.1016/j.medj.2021.03.017 · Cited by 70 · see citing works

Classification of prostate cancer using a protease activity nanosensor library

Dudani, J. S., Ibrahim, M., Kirkpatrick, J. D., Warren, A., & Bhatia, S. N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805337115 · Cited by 69 · see citing works

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

Kaseb, A. O., Vence, L. M., Blando, J. M., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J., Allison, J. P., & Sharma, P. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0605 · Cited by 66 · see citing works

Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA

Kaseb, A., Sanchez, N. S., Sen, S., Kelley, R., Tan, B., Bocobo, A., Lim, K., Abdel-Wahab, R., Uemura, M., Pestana, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3341 · Cited by 66 · see citing works

The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis

Silveira, M. A. D., Bilodeau, S., Greten, T. F., Wang, X. W., & Trinchieri, G. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.02.009 · Cited by 66 · see citing works

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Qin, S., Kudo, M., Meyer, T., Finn, R., Vogel, P., Bai, Y., Guo, Y., Meng, Z., Zhang, T., Satoh, T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.033 · Cited by 66 · see citing works

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

Pinato, D. J., Marron, T. U., Mishra-Kalyani, P. S., Gong, Y. U. T., Wei, G., Szafron, D., Sharon, E., Saeed, A., Jun, T. W., Dharmapuri, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.020 · Cited by 64 · see citing works

T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.

Bian, J., Lin, J., Long, J., Xu, Y., Yang, X., Lu, X., Sang, X., & Zhao, H. (2020) · PubMed Central · Cited by 63 · see citing works

Trajectory of immune evasion and cancer progression in hepatocellular carcinoma

Nguyen, P. H. D., Wasser, M., Tan, C. T., Lim, C. J., Lai, H. L. H., Seow, J. J. W., DasGupta, R., Phua, C. Z. J., Ma, S., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29122-w · Cited by 61 · see citing works

Emerging and Evolving Concepts in Cancer Immunotherapy Imaging

Dercle, L., Sun, S. H., Seban, R., Mekki, A., Sun, R., Tselikas, L., Hans, S., Bernard‐Tessier, A., Bouvier, F. M., Aide, N., et al. (2022) · Radiology · doi:10.1148/radiol.210518 · Cited by 61 · see citing works

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome

Shi, A., Kasumova, G. G., Michaud, W. A., Cintolo-Gonzalez, J., Díaz‐Martínez, M., Ohmura, J. F., Mehta, A., Chien, I., Frederick, D. T., Cohen, S., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb3461 · Cited by 59 · see citing works

Using cell-free DNA for HCC surveillance and prognosis

Tran, N. H., Kisiel, J. B., & Roberts, L. R. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100304 · Cited by 59 · see citing works

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

Zhang, Y., Huang, H., Coleman, M., Žiemys, A., Gopal, P., Kazmi, S. M. A., & Brekken, R. A. (2021) · JCI Insight · doi:10.1172/jci.insight.150735 · Cited by 59 · see citing works

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

Kim, C., Yang, H., Kim, I. H., Kang, B., Kim, H., Kim, H., Lee, W. S., Jung, S., Lim, H. Y., Cheon, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4733 · Cited by 59 · see citing works

Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival

Yu, S., Wang, Y., Hou, J., Li, W.-Y., Wang, X., Xiang, L., Tan, D., Wang, W., Jiang, L., Claret, F. X., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231003 · Cited by 58 · see citing works

Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD ‐1 based immunotherapy in hepatocellular carcinoma

Wu, H., Zheng, X., Pan, T., Yang, X., Chen, X., Zhang, B., Peng, L., & Xie, C. (2022) · International Journal of Cancer · doi:10.1002/ijc.34118 · Cited by 57 · see citing works

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis

Li, X.-S., Li, J., Li, H., & Jiang, T. (2020) · Bioscience Reports · doi:10.1042/bsr20200459 · Cited by 56 · see citing works

Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy

Mei, J., Sun, X., Lin, W., Li, S., Lu, L., Zou, J., Wei, W., & Guo, R. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s325600 · Cited by 51 · see citing works

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors

Zhang, L., Chen, C., Chai, D., Li, C., Guan, Y., Liu, L., Kuang, T., Deng, W., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956533 · Cited by 46 · see citing works

Progress of MRI Radiomics in Hepatocellular Carcinoma

Gong, X.-Q., Tao, Y.-Y., Wu, Y., Liu, N., Yu, X., Wang, R., Zheng, J., Liu, N., Huang, X., Li, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698373 · Cited by 46 · see citing works

Abstract CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

Chow, P. K. H., Chen, M., Cheng, A., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-ct003 · Cited by 44 · see citing works

The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas

Huang, M., He, M., Guo, Y., Li, H., Shen, S., Xie, Y., Li, X., Xiao, H., Fang, L., Li, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3840 · Cited by 42 · see citing works

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

Breeur, M., Ferrari, P., Dossus, L., Jenab, M., Johansson, M., Rinaldi, S., Travis, R. C., His, M., Key, T., Schmidt, J. A., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02553-4 · Cited by 41 · see citing works

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Rizzo, A., Dall’Armellina, S., Pizzuto, D. A., Perotti, G., Zagaria, L., Lanni, V., Treglia, G., Racca, M., & Annunziata, S. (2022) · Cancers · doi:10.3390/cancers14164039 · Cited by 40 · see citing works

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

Haber, P. K., Torres‐Martín, M., Dufour, J., Verslype, C., Marquardt, J. U., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4100 · Cited by 37 · see citing works

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma

Hung, H., Lee, J., Wang, Y., Cheng, C., Wu, T., Lee, C., Wu, T.-J., Chou, H., Chan, K., & Lee, W. (2021) · Cancers · doi:10.3390/cancers13071607 · Cited by 36 · see citing works

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

Budhu, A., Pehrsson, E. C., He, A. R., Goyal, L., Kelley, R. K., Dang, H. T., Xie, C., Monge, C., Tandon, M., Ma, L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101052 · Cited by 33 · see citing works

Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma

Ge, P., Li, S., Wang, W., Li, C., Fu, Y., Feng, Z., Li, L., Zhang, G., Gao, Z., Dang, X., et al. (2020) · Aging · doi:10.18632/aging.102971 · Cited by 33 · see citing works

Biomarkers for response to immunotherapy in hepatobiliary malignancies

Lin, Z., Qin, L., & Chen, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.002 · Cited by 31 · see citing works

Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Teng, W., Lin, C., Lin, P.-T., Hsieh, Y., Ho, M.-M., Hsieh, C.-H., Lin, C., & Lin, S. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01098-4 · Cited by 30 · see citing works

Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma

Tao, Y.-Y., Shi, Y., Gong, X.-Q., Li, L., Li, Z.-M., Yang, L., & Zhang, X. M. (2023) · Cancers · doi:10.3390/cancers15020365 · Cited by 30 · see citing works

Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy

Zhao, B., Wang, W., Li, N., García‐Lezana, T., Che, C., Wang, X., Losic, B., Villanueva, A., & Cunningham, B. T. (2022) · Talanta · doi:10.1016/j.talanta.2022.123256 · Cited by 28 · see citing works

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy

Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 26 · see citing works

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives

Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 26 · see citing works

Artificial Intelligence in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review

Martinino, A., Aloulou, M., Chatterjee, S., Pereira, J. P. S., Singhal, S., Patel, T., Kirchgesner, T., Agnes, S., Annunziata, S., Treglia, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216368 · Cited by 25 · see citing works

Molecular Monitoring of Lymphomas

Schroers‐Martin, J. G., Alig, S., Garofalo, A., Tessoulin, B., Sugio, T., & Alizadeh, A. A. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-050520-044652 · Cited by 19 · see citing works

Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma

Pomyen, Y., Budhu, A., Chaisaingmongkol, J., Forgues, M., Dang, H. T., Ruchirawat, M., Mahidol, C., Wang, X. W., Pupacdi, B., Rabibhadana, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91560-1 · Cited by 19 · see citing works

Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma

Hung, Y., Shao, Y., Lee, J., Hsu, C., Hsu, C., Yang, M., & Chao, Y. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000477 · Cited by 18 · see citing works

Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma

Bell, M. M., Turkbey, E. B., & Escorcia, F. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000435 · Cited by 17 · see citing works

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma

Monge, C., Xie, C., Steinberg, S. M., & Greten, T. F. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s311496 · Cited by 17 · see citing works

Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial

Neely, J., Yao, J. G., Kudo, M., Finn, R. S., Sangro, B., Melero, I., El-Khoueiry, A. B., Tschaika, M., Begic, D., Sama, A. R., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-2145 · Cited by 16 · see citing works

Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood

Cao, Y., Chang, T., Schischlik, F., Wang, K., Sinha, S., Hannenhalli, S. S., Jiang, P., & Ruppin, E. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0092 · Cited by 15 · see citing works

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials

Sidiropoulos, D. N., Stein-O’Brien, G., Danilova, L., Groß, N., Charmsaz, S., Xavier, S., Leatherman, J. M., Wang, H., Yarchoan, M. M., Jaffee, E. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160398 · Cited by 15 · see citing works

The Microbiome and Liver Cancer

Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 14 · see citing works

Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma

Heinrich, B., Ruf, B., Subramanyam, V., Myojin, Y., Lai, C. W., Craig, A. J., Fu, J., Xie, C., Kroemer, A., Greten, T. F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849958 · Cited by 12 · see citing works

Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials

Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 136 · see citing works

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy

Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 131 · see citing works

Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis

Tran, H. L., Zheng, W., Issadore, D., Im, H., Cho, Y., Zhang, Y., Liu, D., Liu, Y., Li, B., Liu, F., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c00706 · Cited by 106 · see citing works

Cancer stem cells and niches: challenges in immunotherapy resistance

Pan, Y., Yuan, C., Zeng, C., Sun, C., Xia, L., Wang, G., Chen, X., Zhang, B., Liu, J., & Ding, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02265-2 · Cited by 110 · see citing works

Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment

Le, J., Dian, Y., Zhao, D., Guo, Z., Luo, Z., Chen, X., Zeng, F., & Deng, G. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02426-3 · Cited by 109 · see citing works

Big data and artificial intelligence in cancer research

Wu, X., Li, W., & Tu, H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.10.006 · Cited by 81 · see citing works

Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma

Salié, H., Wischer, L., D’Alessio, A., Godbole, I., Suo, Y., Otto-Mora, P., Beck, J., Neumann, O., Stenzinger, A., Schirmacher, P., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332837 · Cited by 78 · see citing works

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Cappuyns, S., Piqué-Gili, M., Esteban-Fabró, R., Philips, G., Balaseviciute, U., Pinyol, R., Gris-Oliver, A., Vandecaveye, V., Abril-Fornaguera, J., Montironi, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.016 · Cited by 69 · see citing works

Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment

Cao, M., Deng, Y., Hao, Q., Yan, H., Wang, Q., Dong, C., Wu, J., He, Y., Huang, L., Xia, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02226-7 · Cited by 71 · see citing works

Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy

Cui, M.-R., Zhang, D., Zheng, X. P., Zhai, H., Xie, M., Fan, Q., Wang, L., Fan, C., & Chao, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10010 · Cited by 65 · see citing works

Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma

Zhu, C., Zhang, C., Wang, S., Xun, Z., Zhang, D., Lan, Z., Zhang, L., Chao, J., Liang, Y., Pu, Z., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008686 · Cited by 60 · see citing works

Immunotherapy for hepatocellular carcinoma

Childs, A., Aidoo-Micah, G., Maini, M. K., & Meyer, T. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101130 · Cited by 58 · see citing works

Crosstalk between gut microbiotas and fatty acid metabolism in colorectal cancer

Zhang, H., Tian, Y., Xu, C., Chen, M., Xiang, Z., Gu, L., Xue, H., & Xu, Q. R. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02364-5 · Cited by 52 · see citing works

Development of Polymethine Dyes for NIR‐II Fluorescence Imaging and Therapy

Chen, X., Li, J., Roy, S., Ullah, Z., Gu, J., Huang, H., Yu, C., Wang, X., Wang, H., Zhang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304506 · Cited by 48 · see citing works

Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study

Long, S., Li, M., Chen, J., Zhong, L., Abudulimu, A., Zhou, L., Liu, W., Pan, D., Dai, G., Fu, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009879 · Cited by 45 · see citing works

Role of the gut microbiota in tumorigenesis and treatment

Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 43 · see citing works

Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery

Zhang, S., Deshpande, A. M., Verma, B. K., Wang, H., Mi, H., Yuan, L., Ho, W. J., Jaffee, E. M., Zhu, Q., Anders, R. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0943 · Cited by 42 · see citing works

Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment

Yu, J., Chen, X., Yang, X., & Zhang, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.06.003 · Cited by 40 · see citing works

Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment

Liu, Y., Yang, H., Li, T. X., & Zhang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460282 · Cited by 39 · see citing works

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges

Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 37 · see citing works

Recent progress of microneedles in transdermal immunotherapy: A review

Ai, X., Yang, J., Liu, Z., Guo, T., & Feng, N. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124481 · Cited by 34 · see citing works

ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis

Xie, P., Guo, L., Yu, Q., Zhao, Y., Yu, M., Wang, H., Wu, M., Xu, W., Xu, M., Zhu, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0954 · Cited by 34 · see citing works

Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy

Liu, Z., Wu, C.-Y., Wu, R., Wang, J.-C., Huang, C.-X., Wang, X., Zhang, Y., Zheng, L., Chen, Y., Lao, X., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.006 · Cited by 34 · see citing works

Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study

Long, S., Li, M., Chen, J., Zhong, L., Dai, G., Pan, D., Liu, W., Yi, F., Ruan, Y., Zou, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011126 · Cited by 33 · see citing works

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma

Qin, R., Jin, T., & Xu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326097 · Cited by 29 · see citing works

Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

Yu, X., Qian, J., Ding, L., Pan, C., Liu, X., Wu, Q., Wang, S., Liu, J., Shang, M., Su, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202408788 · Cited by 28 · see citing works

Small-molecule-based targeted therapy in liver cancer

Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 27 · see citing works

Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity

Rana, P. S., Ignatz-Hoover, J. J., Guo, C., Mosley, A. L., Malek, E., Federov, Y., Adams, D., & Driscoll, J. J. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0931 · Cited by 28 · see citing works

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration

Lin, Y., Ou, D., Su, Y., Hsu, C., Hsiao, C., Ko, B., Chen, S., Wang, J., Wang, J.-H., Wu, Y., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.035 · Cited by 32 · see citing works

Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles

Zou, C., Liu, X., Wang, W., He, L., Yin, A., Cao, Z., Zhu, M., Wu, Y., Liu, X., Ma, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03182-8 · Cited by 26 · see citing works

Circulating Gut Microbe-Derived Metabolites Are Associated with Hepatocellular Carcinoma

Banerjee, R., Wehrle, C. J., Wang, Z., Wilcox, J. D., Uppin, V., Varadharajan, V., Mrdjen, M., Hershberger, C. E., Reizes, O., Yu, J. S., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091946 · Cited by 25 · see citing works

Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8+ T cell infiltration

Gan, L., Lü, T., Lu, Y., Song, H., Zhang, J., Zhang, K., Lu, S., Wu, X., Nie, F., Di, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009111 · Cited by 25 · see citing works

Spatial single-cell omics: new insights into liver diseases

Suo, Y., Thimme, R., & Bengsch, B. (2025) · Gut · doi:10.1136/gutjnl-2024-332105 · Cited by 27 · see citing works

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334026 · Cited by 24 · see citing works

TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma

Guo, H., Wang, M., Ni, C., Yang, C., Fu, C., Zhang, X., Chen, X., Wu, X., Hou, J. W., & Wang, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03287-w · Cited by 27 · see citing works

PARK7-driven IGF2BP3–K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma

Zhu, Z., Xia, X., Lu, Y., Li, D., He, X., Zhang, B., Xiong, G., Zhang, W., Liang, H., & Zhu, H. J. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103869 · Cited by 24 · see citing works

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar, R. D., Salem, R., Finn, R. S., Greten, T. F., Goldberg, S. N., & Chapiro, J. (2024) · Radiology · doi:10.1148/radiol.232875 · Cited by 25 · see citing works

A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Han, J. W., Lee, S. K., Kwon, J. H., Nam, S. W., Yang, H., Bae, S. H., Kim, J. H., Nam, H., Kim, C. W., Lee, H. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3978 · Cited by 22 · see citing works

RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation

Han, H., Shi, Q., Zhang, Y., Ding, M., He, X.-Z., Liu, C., Zhao, D., Wang, Y., Du, Y.-P., Zhu, Y.-C., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03140-y · Cited by 20 · see citing works

A N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis

Guo, Z., Li, Z., Guo, J., Gan, L., Mo, H., Zhang, J., Fu, Y., Wang, Y., Jin, M., Wu, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07248-7 · Cited by 19 · see citing works

Role of peritumoral tissue analysis in predicting characteristics of hepatocellular carcinoma using ultrasound-based radiomics

Qian, H., Huang, Y., Xu, L., Fu, H., & Lu, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-62457-6 · Cited by 18 · see citing works

Advancing Hepatocellular Carcinoma Management Through Peritumoral Radiomics: Enhancing Diagnosis, Treatment, and Prognosis

Huang, Y., & Qian, H. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s493227 · Cited by 18 · see citing works

Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9

Hou, C., Lv, P., Yuan, H.-F., Zhao, L., Wang, Y., Zhang, H., Yang, G., & Zhang, X.-D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01299-4 · Cited by 17 · see citing works

A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma

Xu, J., Wang, T., Li, J., Wang, Y., Zhu, Z., Xiao, F., Wang, J., Zhang, Z., Cai, W., Song, R., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00979-6 · Cited by 17 · see citing works

Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma

Liu, Z., Yang, L., Liu, C., Wang, Z., Xu, W., Lu, J., Wang, C., & Xu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371829 · Cited by 17 · see citing works

Radiomic features of primary retroperitoneal sarcomas: a prognostic study

Pasquali, S., Iadecola, S., Vanzulli, A., Infante, G., Bologna, M., Corino, V., Greco, G. F., Vigorito, R., Morosi, C., Beretta, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115120 · Cited by 17 · see citing works

Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma

Li, Y., Chen, Z., Wang, D., Du, W. T., Zhu, N., Shen, X., Mao, X., Su, Y., Qin, L., Chen, D., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02367-9 · Cited by 18 · see citing works

Role of UFMylation in tumorigenesis and cancer immunotherapy

Ding, L., Jiang, X. M., Li, T., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454823 · Cited by 16 · see citing works

Triterpenes from Ganoderma lucidum inhibit hepatocellular carcinoma by regulating enhancer-associated lncRNA in vivo

Zhao, R., Zhang, C., Tang, C., Wu, X., Hu, S., Luo, Q., Jia, N., Fan, L., Wang, Y., Jiang, W., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118706 · Cited by 17 · see citing works

The Gut Microbiome Controls Liver Tumors via the Vagus NervePreprint

Bauer, K. C., Trehan, R., Ruf, B., Myojin, Y., Benmebarek, M.-R., Ma, C., Seifert, M., Nur, A., Qi, J., Huang, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576951 · Cited by 18 · see citing works

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)

Jin, Z.-C., Wei, J., Xiao, Y., Si, A., Chen, J.-J., Zhu, X., Li, J., Nie, F., Ding, R., Zhou, H., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001593 · Cited by 16 · see citing works

Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via exosomes in gastrointestinal tumors

Cao, L., & Ouyang, H. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374742 · Cited by 15 · see citing works

Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma

Gao, Y., Gong, Y., Lu, J., Yang, Y., Zhang, Y., Xiong, Y., & Shi, X. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116294 · Cited by 15 · see citing works

A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study

Li, Y., Li, X., Xiao, X., Cheng, J., Liu, C., Liu, C., Cai, P., Chen, W., Zhang, H., & Li, X. (2024) · European Radiology · doi:10.1007/s00330-024-11255-9 · Cited by 15 · see citing works

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Nosaka, T., Murata, Y., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., Imamura, Y., & Nakamoto, Y. (2024) · Cancers · doi:10.3390/cancers16091785 · Cited by 14 · see citing works

Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma

Lim, M., Espinoza, M., Huang, Y., Franses, J. W., Zhu, H., & Hsiehchen, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.61735 · Cited by 14 · see citing works

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma

Zhang, Y., Ma, Y., Ma, E., Chen, X., Zhang, Y., Yin, B., & Zhao, J. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.165 · Cited by 14 · see citing works

A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma

Zheng, H., Cheng, J., Zhuang, Z., Li, D., Yang, J., Yuan, F., Fan, X., & Liu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412277 · Cited by 13 · see citing works

Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity

Weng, Y., Wang, L., Wang, Y., Xu, J., Fan, X., Luo, S., Hua, Q., Xu, J., Liu, G., Zhao, K.-B., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0589 · Cited by 13 · see citing works

Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis

He, B., Zhao, R., Zhang, B., Pan, H., Liu, J., Huang, L., Wei, Y., Yang, D., Liang, J., Wang, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186291 · Cited by 12 · see citing works

Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging

Quan, Z., Gao, Y., Sun, B., Guo, Y., Jin, Z., Hao, N., Jiang, D., Zheng, C., Li, X., & Chen, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00820-z · Cited by 12 · see citing works

Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma

Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 12 · see citing works

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

Vianello, C., Monti, E., Leoni, I., Galvani, G., Giovannini, C., Piscaglia, F., Stefanelli, C., Gramantieri, L., & Fornari, F. (2024) · Cancers · doi:10.3390/cancers16040766 · Cited by 11 · see citing works

Intertumoral Heterogeneity Based on MRI Radiomic Features Estimates Recurrence in Hepatocellular Carcinoma

Dong, M., Li, C., Zhang, L., Zhou, J., Xiao, Y., Zhang, T., Jin, X., Fang, Z., Zhang, L., Han, Y., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29428 · Cited by 11 · see citing works

Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

Urquijo-Ponce, J. J., Mateu, C. A., Sánchez, M. L., Castelló-Miralles, I., & Moisés Diago, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i19.2512 · Cited by 11 · see citing works

Unveiling Tim-3 immune checkpoint expression in hepatocellular carcinoma through abdominal contrast-enhanced CT habitat radiomics

Tang, Z., Wang, W., Gao, B., Liu, X., Liu, X., Zhuo, Y., Du, J., Ai, F., Yang, X., & Gu, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1456748 · Cited by 11 · see citing works

Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis

Qiao, Y., Xie, D., Li, Z., Cao, S., & Zhao, D. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2435598 · Cited by 11 · see citing works

Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma

Jiang, J., Feng, K., Zhang, L., & Ma, K. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000086 · Cited by 10 · see citing works

Machine learning-based radiomics model: prognostic prediction and mechanism exploration in patients with endometrial cancer

Zhang, Y., Bao, X., Wang, Y., Li, L., Liu, L., & Wu, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00836-5 · Cited by 9 · see citing works

Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications

Piao, M., Zhang, N., Li, J., Li, C., Xun, Z., Zhang, L., Wang, S., Sun, B., Li, S., Xu, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114052 · Cited by 9 · see citing works

Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy

Li, T., Guo, S., Xu, C., Zhang, M., Lyu, C., Xu, H., Hou, Z., Zhang, M., Li, X., Ren, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010534 · Cited by 9 · see citing works

Advancements in immunotherapy for hepatocellular carcinoma

Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8 · see citing works

A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy

Zheng, Z., Mei, J., Guan, R., Zhang, J., Xiong, X., Gan, J., Li, S., & Guo, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03713-6 · Cited by 8 · see citing works

Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models

Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16871 · Cited by 8 · see citing works

Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinomaPreprint

Wu, Z., Boen, J., Jindal, S., Basu, S., Bieniosek, M. F., He, S., LaPelusa, M. B., Mayer, A. T., Kaseb, A. O., Zou, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.656869 · Cited by 8 · see citing works

Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment

Zhao, H., Ren, R., Zhang, X., Zhan, M., Cui, J., Zhang, J., Liu, X., Wu, L., Chen, Y., Zhou, Y. J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1298 · Cited by 7 · see citing works

Natural exosome-like nanovesicles from Salvia chinensis Benth induce ferroptosis to suppress hepatocellular carcinoma progression via AMPK/Nrf2/xCT axis

Liang, Z., Fang, X., Zhang, Z., Tao, M., Gong, W.-H., Jian, H., Tan, X., & Zeng, P. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111928 · Cited by 7 · see citing works

Biomaterials for biomarker imaging and detection

Wang, Y., Huang, X., Wu, G., Wu, W., Li, S., Su, C., Li, L., & Lv, Q. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.049 · Cited by 7 · see citing works

Acteoside as a rising star for clinical treatment: Current fundamental research and future outlooks

Zhang, F.-K., Jia, K., Wang, H., Liu, R., Xue, X., Huo, Z.-X., & Li, X. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.08.007 · Cited by 7 · see citing works

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Scheiner, B., Lombardi, P., D’Alessio, A., Kim, G., Tafavvoghi, M., Petrenko, O., Goldin, R. D., Fulgenzi, C. A. M., Torkpour, A., Balcar, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010975 · Cited by 7 · see citing works

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab

Kocheise, L., Kempski, J., Tang, Y., Balcar, L., Berger, V., Tomczak, M., Gorgulho, J., Masood, R., Giehren, F., Schmidt, C., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102138 · Cited by 7 · see citing works

From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC ?

Decraecker, M., Blanc, J., Amintas, S., & Manaud, G. (2026) · Liver International · doi:10.1111/liv.70684 · Cited by 7 · see citing works

Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment

Liu, Q., Zhu, W., Song, F., Lou, T., He, L., Zhou, W., & Feng, Z. (2024) · Meta-Radiology · doi:10.1016/j.metrad.2024.100098 · Cited by 7 · see citing works

Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Murata, Y., Nosaka, T., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., & Nakamoto, Y. (2024) · Cancers · doi:10.3390/cancers16132410 · Cited by 7 · see citing works

Golgi protein 73: the driver of inflammation in the immune and tumor microenvironment

Feng, P., Hu, X., Zhou, S., Liu, X., Zeng, L., & Liu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1508034 · Cited by 7 · see citing works

Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer

Feng, Y., Fang, L., & Cao, G. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.132 · Cited by 9 · see citing works

Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression

Zhou, M., Zhou, Z., Hu, L., Chen, S., Meng, F., Chen, J., & Shen, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06106-0 · Cited by 7 · see citing works

An integrated platform for decoding hydrophilic peptide fingerprints of hepatocellular carcinoma using artificial intelligence and two-dimensional nanosheets

Li, Z., Ma, B., Shui, S., Tu, Z., Peng, W., Chen, Y., Zhou, J., Lan, F., Ying, B., & Wu, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00700j · Cited by 6 · see citing works

Integrating anoikis and ErbB signaling insights with machine learning and single-cell analysis for predicting prognosis and immune-targeted therapy outcomes in hepatocellular carcinoma

Fang, H., Chen, X., Zhong, Y., Wu, S., Ke, Q., Huang, Q., Wang, L., & Zhang, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446961 · Cited by 6 · see citing works

Hollow MnO2@PDLIM2 nanoplatform inhibits hepatocellular carcinoma immune evasion and progression by regulating TBK1

Liu, Z., Hu, Q., Wang, J., Zhu, X., Sun, J., Zhang, G., Fang, R., Wang, R., Zhang, B., Shi, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161835 · Cited by 6 · see citing works

Predicting Immunotherapy Response in Unresectable Hepatocellular Carcinoma: A Comparative Study of Large Language Models and Human Experts

Xu, J., Wang, J., Li, J., Zhu, Z., Xiao, F., Cai, W., Song, R., Wang, T. F., & Li, H. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02192-1 · Cited by 6 · see citing works

A Novel Nomogram to Predict Prognosis in Elderly Early-Stage Hepatocellular Carcinoma Patients After Ablation Therapy

Tang, X., Wang, Q., Jin, R., & Hu, C. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s459250 · Cited by 6 · see citing works

Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab

Kim, J. H., Han, J. W., Cho, H. S., Jang, J. W., Tak, K. Y., & Sung, P. S. (2025) · Cancers · doi:10.3390/cancers17243967 · Cited by 5 · see citing works

NRF2–COX2–PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma

Yamamoto, S., Kodama, T., Kuwano, A., Maesaka, K., Hashidate‐Yoshida, T., Shindou, H., Takeda, H., Shirai, K., Myojin, Y., Murai, K., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001677 · Cited by 5 · see citing works

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma

Wang, Y., Li, F., Li, J., Huang, T., Huang, T., Zhang, N., Li, Y., Xun, Z., Zhu, Z., Tan, Q., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.003 · Cited by 5 · see citing works

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio in Patients with Hepatocellular Carcinoma Receiving HAIC-Based Conversion Hepatectomy: A Dual-Center Retrospective Cohort Study

Li, D., Fan, Y., He, B., Tang, Y., Deng, G., Guo, R., Deng, M., & Tang, D. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s523194 · Cited by 5 · see citing works

Identification of Two Distinct Immune Subtypes in Hepatitis B Virus (HBV)-Associated Hepatocellular Carcinoma (HCC)

Battista, D. D., Yakymi, R., Scheibe, E., Sato, S., Gerstein, H., Markowitz, T. E., Lack, J., Mereu, R., Manieli, C., Zamboni, F., et al. (2024) · Cancers · doi:10.3390/cancers16071370 · Cited by 5 · see citing works

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Nishida, N. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0739 · Cited by 5 · see citing works

Single-Cell Transcriptomic Profiling Reveals That Macrophage-Induced Angiogenesis Contributes to Immunotherapy Resistance in Hepatocellular Carcinoma

Pan, X., Liao, B., Hu, Z., & Xiong, Y. (2026) · Biology · doi:10.3390/biology15010095 · Cited by 4 · see citing works

Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma

Chen, Y., Wang, K., Zhang, X., Tao, D., Shang, Y., Wang, P., Li, Q., & Liu, Y. (2024) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-024-01061-8 · Cited by 4 · see citing works

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

Chen, X., Kou, L., Xie, X., Su, S., Li, J., & Li, Y. (2024) · Immunology · doi:10.1111/imm.13751 · Cited by 9 · see citing works

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Rizzo, A., Ricci, A. D., Federico, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803133 · Cited by 105 · see citing works

Immunotherapy for hepatocellular carcinoma

Childs, A., Aidoo-Micah, G., Maini, M. K., & Meyer, T. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101130 · Cited by 58 · see citing works

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance

Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 27 · see citing works

Recent advance in immune checkpoint inhibitors-based therapy of advanced hepatocellular carcinoma

Mo, J., Guo, Z., Zhang, S., Huang, G., & Cai, T. (2024) · Archives of Medical Science · doi:10.5114/aoms/188722